Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy

Blood Cancer J. 2021 Jun 25;11(6):121. doi: 10.1038/s41408-021-00513-4.

Authors

Rajshekhar Chakraborty¹, Lisa Rybicki², Jason Valent³, Alex V Mejia Garcia³, Beth M Faiman³, Jack Khouri³, Christy J Samaras³, Faiz Anwer³, Alok A Khorana⁴

Affiliations

¹ Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
² Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
³ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁴ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. khorana@ccf.org.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Aspirin / administration & dosage*
Bortezomib / administration & dosage
Bortezomib / adverse effects
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Dexamethasone / administration & dosage
Dexamethasone / adverse effects
Disease-Free Survival
Female
Heparin, Low-Molecular-Weight / administration & dosage*
Humans
Incidence
Male
Middle Aged
Multiple Myeloma* / drug therapy
Multiple Myeloma* / mortality
Retrospective Studies
Survival Rate
Thromboembolism* / chemically induced
Thromboembolism* / mortality
Thromboembolism* / prevention & control
Warfarin / administration & dosage*

Substances

Heparin, Low-Molecular-Weight
Warfarin
Bortezomib
Dexamethasone
Cyclophosphamide
Aspirin